BRAF Mutation Analysis in Metastatic Colon Cancer and Non-Small Cell Lung Cancer
BRAF, Colon Cancer Mutation Analysis
Specimen Collection Criteria
Collect: Paraffin-embedded tissue. A paraffin block must be submitted. (Slides or paraffin shavings are not acceptable.) Submit formalin-fixed, paraffin-embedded block with corresponding H&E slide. Tissue should be well fixed and well processed. Average tissue size 5.0 mm2.
- DNA will be assessed for quality. If it is deemed unacceptable, testing will be cancelled with client notification.
- The specimen must be accompanied by a completed requisition and must contain the patient name, date of birth, collection date, ordering physician, and source of specimen.
Physician Office/Drawsite Specimen Preparation
Maintain paraffin-embedded tissue at room temperature (20-26°C or 68-78.8°F) until transport.
Preparation for Courier Transport
Transport: Paraffin-embedded tissue, at room temperature (20-26°C or 68-78.8°F).
- Decalcified tissue.
- Fixatives other than 10% neutral buffered formalin.
- Improper labeling or inadequate information.
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): Indefinitely
Refrigerated (2-8°C or 36-46°F): Unacceptable
Frozen (-20°C/-4°F or below): Unacceptable
Specimen Storage in Department Prior to Disposal:
Room Temperature (20-26°C or 68-78.8°F): 7 days
Royal Oak Clinical Molecular Pathology Laboratory.
Once per week, usually Wednesday.
Results available in 10 business days.
No BRAF mutations detected OR presence of BRAF mutations is associated with lack of response to anti-EGFR therapy.
Tissue sections are reviewed by a pathologist and relevent tumor is selected for analysis. DNA is isolated from the sample and quantified. The DNA is amplified using reagents supplied in a BRAF mutation detection kit (EntroGen, Inc., Tarzana CA). The samples are analyzed using an ABI 7500 FAST Real-Time PCR Instrument (Applied Biosystems Inc, Foster City, CA). False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample.
Wild-type or BRAF mutation present with specific mutation listed (V600E, V600A, and V600G).
- The BRAF Mutation Analysis Assay provides additional guidance in therapeutic treatment decisions for patients with metastatic colorectal adenocarcinoma as well as those with non-small lung cancer (NSCLC).
- Mutations in the BRAF gene, a known downstream signaling molecule in the EGFR signaling pathway, have been described in approximately 15-30% of lung adenocarcinoma and 30-50% of colon adenocarcinoma.
- Recent studies have found mutations in the BRAF gene to be associated with a poor prognosis. Studies have also found BRAF mutations more frequent in patients who show limited clinical response or develop disease progression with targeted tyrosine kinase inhibitor (TKI) treatments. As a result, determining the BRAF mutational status of a tumor may guide therapeutic decision making for patients with NSCLC or colon adenocarcinoma.
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.
This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills,
Grosse Pointe, Royal Oak, and Troy campuses.